RPAP3

Across TCGA pan-cancer cohorts, RPAP3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RPAP3 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher RPAP3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RPAP3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LSCC, CCRCC, and LUAD are the cancer types where RPAP3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	II,III,IV	0.939	0.466	.003	34	view →
CCRCC	DFS	Quartile	III,IV	0.353	0.726	<.001	28	view →
LUAD	OS	Median	All	0.651	0.847	.011	8	view →
PDAC	OS	Median	IV	0.951	0.381	.006	6	view →
HNSC	DFS	Median	IV	1.000	0.413	.033	2	view →
GBM	OS	Quartile	All	0.722	0.910	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RPAP3–LSCC (DFS)

Open the LSCC breakdown →